These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 31570474)

  • 21. Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study.
    Nakamura K; Kato M; Shukuya T; Mori K; Sekimoto Y; Ihara H; Kanemaru R; Ko R; Shibayama R; Tajima K; Koyama R; Shimada N; Nagashima O; Takahashi F; Sasaki S; Takahashi K
    BMC Cancer; 2017 May; 17(1):302. PubMed ID: 28464801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
    Kato T; Masuda N; Nakanishi Y; Takahashi M; Hida T; Sakai H; Atagi S; Fujita S; Tanaka H; Takeda K; Satouchi M; Namba Y; Tamura T
    Lung Cancer; 2017 Feb; 104():111-118. PubMed ID: 28212992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Negative Impact of Coexisting Interstitial Lung Disease on Clinical Outcomes in Small-cell Lung Cancer Patients.
    Akaike K; Saruwatari K; Okabayashi H; Hamada S; Jodai Y; Jodai T; Sakata S; Iyama S; Sato R; Iriki T; Tomita Y; Saeki S; Ichiyasu H; Fujii K
    Anticancer Res; 2018 Nov; 38(11):6543-6550. PubMed ID: 30396984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Independent review of interstitial lung disease associated with death in TRIBUTE (paclitaxel and carboplatin with or without concurrent erlotinib) in advanced non-small cell lung cancer.
    Yoneda KY; Shelton DK; Beckett LA; Gandara DR
    J Thorac Oncol; 2007 Jun; 2(6):537-43. PubMed ID: 17545850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute exacerbation predicting poor outcomes in idiopathic interstitial pneumonia and advanced lung cancer patients undergoing cytotoxic chemotherapy.
    Miyamoto A; Michimae H; Nakahara Y; Akagawa S; Nakagawa K; Minegishi Y; Ogura T; Hontsu S; Date H; Takahashi K; Homma S; Kishi K;
    Sci Rep; 2024 May; 14(1):10162. PubMed ID: 38702426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.
    Sugano T; Seike M; Saito Y; Kashiwada T; Terasaki Y; Takano N; Hisakane K; Takahashi S; Tanaka T; Takeuchi S; Miyanaga A; Minegishi Y; Noro R; Kubota K; Gemma A
    Thorac Cancer; 2020 Apr; 11(4):1052-1060. PubMed ID: 32096610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease.
    Enomoto Y; Inui N; Imokawa S; Karayama M; Hasegawa H; Ozawa Y; Matsui T; Yokomura K; Suda T
    Cancer Chemother Pharmacol; 2015 Sep; 76(3):499-505. PubMed ID: 26134440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between acute exacerbation and progressive pulmonary fibrosis in interstitial lung disease: a retrospective cohort study.
    Zhai L; Wang Z; Yu W
    Ther Adv Respir Dis; 2024; 18():17534666241276800. PubMed ID: 39235441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease.
    Hanibuchi M; Kakiuchi S; Atagi S; Ogushi F; Shimizu E; Haku T; Toyoda Y; Azuma M; Kondo M; Kawano H; Otsuka K; Sakaguchi S; Nokihara H; Goto H; Nishioka Y
    Lung Cancer; 2018 Nov; 125():93-99. PubMed ID: 30429044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.
    Ando M; Okamoto I; Yamamoto N; Takeda K; Tamura K; Seto T; Ariyoshi Y; Fukuoka M
    J Clin Oncol; 2006 Jun; 24(16):2549-56. PubMed ID: 16735708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current pharmacotherapies for advanced lung cancer with pre-existing interstitial lung disease : A literature review and future perspectives.
    Hanibuchi M; Ogino H; Sato S; Nishioka Y
    J Med Invest; 2024; 71(1.2):9-22. PubMed ID: 38735730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Surgical Treatment of Lung Cancer Combined with Interstitial Lung Disease].
    Huang C; Ma C; Wu Q; Jiao P; Sun Y; Tian W; Yu H; Huang W; Wang Y; Tong H
    Zhongguo Fei Ai Za Zhi; 2020 May; 23(5):343-350. PubMed ID: 32429636
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
    Kashiwabara K; Semba H; Fujii S; Tsumura S
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An analysis of the clinical features of lung cancer in patients with connective tissue diseases.
    Saijo A; Hanibuchi M; Goto H; Toyoda Y; Tezuka T; Nishioka Y
    Respir Investig; 2017 Mar; 55(2):153-160. PubMed ID: 28274531
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interstitial lung disease in patients with small cell lung cancer.
    Miyazaki K; Satoh H; Kurishima K; Nakamura R; Ishikawa H; Kagohashi K; Hizawa N
    Med Oncol; 2010 Sep; 27(3):763-7. PubMed ID: 19657749
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of second-line chemotherapy for patients with advanced non-small cell lung cancer complicated by interstitial lung disease.
    Otsuka K; Nokihara H; Mitsuhashi A; Ozaki R; Yabuki Y; Yoneda H; Ogino H; Nishioka Y
    Thorac Cancer; 2022 Nov; 13(21):2978-2984. PubMed ID: 36106507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non-small cell lung cancer.
    Saito Y; Sasaki S; Oikado K; Tominaga J; Sata M; Sakai F; Kato T; Iwasawa T; Kenmotsu H; Kusumoto M; Baba T; Endo M; Fujiwara Y; Sugiura H; Yanagawa N; Ito Y; Sakamoto T; Ohe Y; Kuwano K
    Cancer Sci; 2021 Apr; 112(4):1495-1505. PubMed ID: 33098725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anticancer drug treatment for advanced lung cancer with interstitial lung disease.
    Otsubo K; Okamoto I; Hamada N; Nakanishi Y
    Respir Investig; 2018 Jul; 56(4):307-311. PubMed ID: 29764748
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study.
    Sekine A; Satoh H; Baba T; Ikeda S; Okuda R; Shinohara T; Komatsu S; Hagiwara E; Iwasawa T; Ogura T; Kato T
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1245-52. PubMed ID: 27130459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of acute exacerbation of interstitial lung disease associated with chemotherapy in patients with lung cancer: A feasibility of S-1.
    Kakiuchi S; Hanibuchi M; Tezuka T; Saijo A; Otsuka K; Sakaguchi S; Toyoda Y; Goto H; Kawano H; Azuma M; Ogushi F; Nishioka Y
    Respir Investig; 2017 Mar; 55(2):145-152. PubMed ID: 28274530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.